Zora Biosciences Commercializes VTT's Biotechnology Expertise
News Jun 27, 2007
VTT Technical Research Center of Finland has launched a spin-off company, Zora Biosciences Oy. “Zora’s speciality field of metabolomics is a major driver of biomedical and pharmaceutical research”, says Matej Oresic, founder and chairman of the board.
Zora’s business model is two-fold. Zora will provide laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics. Also, based on this advanced laboratory expertise Zora will develop prognostic and diagnostic biomarkers for human diseases as well as drug safety and efficacy monitoring.
Zora will expand its biomarker portfolio for licensing the discoveries to laboratory assay providers. At present, Zora’s biomarker portfolio includes a pdiscovery for screening patients susceptible to side effects of statins, which are powerful cholesterol lowering drugs. Statin medication is used by millions world-wide as part of their treatment regimen for cardiovascular diseases.
Zora is also developing prognostic and diagnostics tools for improved healthcare management of diabetes and coronary artery disease among other indication areas.
Zora is funded by VTT, Slovenian private investor Gomar D.D., and Seedcap II Ky, managed by Innofinance Oy.
“Zora has strong potential for rapid business growth and internationalization, which has attracted a committed investor base for the company”, says Reini Hurme, Zora CEO. Globally there is only a handful of companies specializing in metabolomics, in the Nordic countries Zora is the only one.
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE